《大行報告》大摩下調阿里健康(00241.HK)目標價至5.2元 評級「減持」
摩根士丹利發表報告指,預計阿里健康(00241.HK)在非藥品庫存管理單位(SKU)擴張和消費者健康意識不斷提高的推動下,2024至26財年各年收入按年增幅料分別13%、20%及16%。假設毛利率和營運槓桿穩定擴張,該行對2024至26財年各年列賬淨利潤率預測分別為2%、2.7%及3.6%。
該行表示,基於內地消費存在不確定因素,將每股盈測下調3%至6%,相應地將終端增長預測由4%下調至3%,並將目標價由5.5元下調至5.2元,評級「減持」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.